Kevin leads the business development efforts to form research collaboration partnerships with biopharma companies. Over the years, Kevin has worked in small-to-midsize biotechs and CROs gathering a wide spectrum of experience in pre- and post-IND development. With his previous role at Integrium, he has helped kickstart an investment arm leading equity and bridge financing investments with micro-cap and small-cap public biopharma companies.
AI-driven Drug Discovery Platform for Splicing Driven Diseases
Introduction to Envisagenics’ SpliceCore drug discovery platform and its application of RNA-splicing analytics to identify new therapeutic targets. The impact of transparent machine learning algorithms for downstream experimental validations. Case study – translating a novel splicing derived target identified by SpliceCore into the wet lab.